A Phase 1 interventional study of Imlunestrant in Hepatic Insufficiency and Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hepatic Insufficiency by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Hepatic Insufficiency · Eli Lilly and Company.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 12 in phase 1, and was the 6th registered.
113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.
Browse Hepatic Insufficiency studies →2 of the 12 studies in Hepatic Insufficiency by Eli Lilly and Company are open now, in 4 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Hungary
Ages 18–85 · Healthy volunteers
Eli Lilly and Company · Sites in Hungary, New Zealand, Slovakia
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is close to the median of 29 across 100 interventional studies indexed under Hepatic Insufficiency.
Median enrollment 34 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
2 of the studies in Hepatic Insufficiency by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07165002Eli Lilly and CompanyA Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment | 2026-11 |
| NCT07401862Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Hepatic Insufficiency by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function. The side effects and tolerability of Imlunestrant will also be evaluated. The study may last up to 46 days for each participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Participants:
Healthy Participants:
- Healthy females as determined by medical history, physical examination, and other screening procedures, with normal liver function
Participants with Impaired Liver Function:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of Imlunestrant 400 milligrams (mg) administered orally on Day 1 in fasted state.
Drug: Imlunestrant
Participants received a single dose of Imlunestrant 400 mg administered orally on Day 1 in fasted state.
Drug: Imlunestrant
Participants received a single dose of Imlunestrant 400 mg administered orally on Day 1 in fasted state.
Drug: Imlunestrant
Participants received a single dose of Imlunestrant 200 mg administered orally on Day 1 in fasted state.
Drug: Imlunestrant
Administered orally.
Also known as: LY3484356
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant
PK: Cmax of Imlunestrant is reported.
Time frame: Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)
PK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant
AUC(0-t) of Imlunestrant is reported.
Time frame: Day 1 (Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours post dose)
| Milestone | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Started | 9 | 6 | 6 | 6 |
| Received at least one dose of study drug | 9 | 6 | 6 | 6 |
| Completed | 9 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
PK: Cmax of Imlunestrant is reported.
| nanograms per milliliter (ng/mL) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant | 58.0 ± 56 | 74.9 ± 47 | 87.6 ± 51 | 46.2 ± 49 |
AUC(0-t) of Imlunestrant is reported.
| nanograms*hour per milliliter (ng*h/mL) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) |
|---|---|---|---|---|
| PK: Area Under the Concentration-time Curve From 0 to the Last Measurable Concentration (AUC[0-t]) of Imlunestrant | 1970 ± 51 | 2410 ± 27 | 4320 ± 50 | 2820 ± 47 |
Collected over Baseline up to 18 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imlunestrant (Normal Hepatic Function) | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Imlunestrant (Mild Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Imlunestrant (Moderate Hepatic Impairment) | 0/6 (0%) | 1/6 (16.7%) | 2/6 (33.3%) |
| Imlunestrant (Severe Hepatic Impairment) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) |
|---|---|---|---|---|
| Portal vein thrombosisHepatobiliary disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| Event | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/9 | 0/6 | 2/6 | 1/6 |
| Abdominal pain upperGastrointestinal disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| VomitingGastrointestinal disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| FallInjury, poisoning and procedural complications | 0/9 | 0/6 | 0/6 | 1/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 0/6 | 0/6 | 1/6 |
| HeadacheNervous system disorders | 0/9 | 0/6 | 1/6 | 1/6 |
| InsomniaPsychiatric disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| PruritusSkin and subcutaneous tissue disorders | 0/9 | 0/6 | 1/6 | 0/6 |
| RashSkin and subcutaneous tissue disorders | 0/9 | 0/6 | 0/6 | 1/6 |
All enrolled participants.
| Age, Continuous(years) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Mean | 60.3 ± 5.0 | 66.7 ± 3.1 | 59.2 ± 8.3 | 57.3 ± 3.1 | 60.8 ± 6.0 |
| Sex: Female, Male(Participants) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Female | 9 | 6 | 6 | 6 | 27 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 3 | 3 | 15 |
| Not Hispanic or Latino | 5 | 1 | 3 | 3 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 8 | 6 | 5 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Imlunestrant (Normal Hepatic Function) | Imlunestrant (Mild Hepatic Impairment) | Imlunestrant (Moderate Hepatic Impairment) | Imlunestrant (Severe Hepatic Impairment) | Total |
|---|---|---|---|---|---|
| United States | 9 | 6 | 6 | 6 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Feb 2024, 19 months.
Results were first posted in Nov 2025, 1 year 8 months after primary completion.
Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 19 months is above that.
Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imlunestrant